Drugs / AMG 598
last change Dec 2019 re-read 2 minutes ago

AMG 598

Developed for
obesity disorder
Investigated by
Amgen

Trials 1 · a red edge is where a trial was stopped

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03757130 Nov 2018 → Dec 2019 obesity disorder Amgen Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AMG 598 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03757130
Route Subcutaneous “AMG 598 administered by subcutaneous injection” NCT03757130